Anteris Technologies Global Corp. Common Stock
AVRAnteris Technologies Global Corp. (AVR) is a medical device company specializing in the development and commercialization of advanced technologies for the treatment of cardiovascular diseases. It focuses on innovative solutions such as transcatheter aortic valve replacement (TAVR) systems designed to improve patient outcomes and procedural efficiency.
Company News
Anteris Technologies completed a $90 million strategic investment from Medtronic and a $230 million underwritten public offering, totaling $320 million in capital. The funding will support execution of the global PARADIGM trial and advance commercialization of the DurAVR® Transcatheter Heart Valve for treating aortic stenosis.
Anteris Technologies closed a $320 million capital raise consisting of a $200 million underwritten public offering of 40 million shares at $5.75 per share and a $120 million private placement to Medtronic. The company will use proceeds to advance its DurAVR® Transcatheter Heart Valve in the PARADIGM Trial, expand manufacturing capabilities, and ...
Anteris Technologies announced a $200 million public offering of 34.78 million shares at $5.75 per share, with an expected closing on January 22, 2026. Additionally, Medtronic agreed to invest up to $90 million in a private placement representing 16-19.99% ownership. Proceeds will fund the PARADIGM Trial for the DurAVR® Transcatheter Heart Valve...
Anteris Technologies received FDA approval to commence patient recruitment for its PARADIGM Trial, evaluating the DurAVR® Transcatheter Heart Valve across the United States, Europe, and Canada. The company advanced regulatory activities, strengthened operational systems, and reported $59.3 million in net operating cash outflows for the first nin...
Anteris Technologies has enrolled and treated the first patients in its global PARADIGM Trial for the DurAVR® Transcatheter Heart Valve, a study comparing the device's safety and effectiveness against existing transcatheter aortic valve replacements.
